AEGiS-15IAC: Double blind placebo controlled study of exercise and oxandrolone on lean mass, fat distribution, blood lipids, bone density and training markers in HIV infected men and women on HAART.

15th International AIDS Conference

Bangkok, Thailand - July 11-16, 2004

Double blind placebo controlled study of exercise and oxandrolone on lean mass, fat distribution, blood lipids, bone density and training markers in HIV infected men and women on HAART.

Int Conf AIDS 2004 Jul 11-16; 15:(abstract no. MoOrB1059)

Smith BA, Raper JL, Weaver MT, Bittner VA, Gower B, Hunter GR, Ottery FD, Pakapong Y, Saag MS
University of Maryland, Baltimore, Baltimore, Maryland, United States

BACKGROUND: Consequences of HAART places patients at risk for cardiovascular disease and other problems. The aim of this double blind, placebo controlled study was to examine the effects of aerobic/resistive exercise with and without oxandrolone on body composition, blood lipids, and exercise markers in HIV infected adults with fat redistribution and metabolic changes associated with HAART.

METHODS: Subjects were randomly assigned to oxandrolone plus exercise or oxandrolone placebo plus exercise. At baseline and week 12 we measured fat mass (FM), fat free mass (FFM) using dual energy x-ray absorptiometry (DEXA), abdominal adipose tissue using computed tomography (CT) scan, oxygen use (VO2) and time on treadmill (TOT). Thirty-one subjects completed the 12-week intervention.

RESULTS: Subjects in both groups lost weight, decreased body mass index, abdominal adipose, triglycerides and increased VO2Peak. Subjects on oxandrolone significantly increased FFM and TOT when compared to placebo. There was a trend to wards a decrease in visceral adipose; however, it was not significant. Positive changes in the oxandrolone group were offset by negative changes in lipids. [table: see text]

CONCLUSIONS: Subjects in both groups benefited from this intervention. Those who received oxandrolone had the added benefit of an increase in FFM and functional capacity as measured by TOT; however, because of the impact of oxandralone on lipids, providers are urged to weigh the risks and benefits associated with short term oxandralone administration in this population.

Keywords: AEGIS, Antiretroviral Therapy, Highly Active, Acquired Immunodeficiency Syndrome, HIV Seropositivity, Oxandrolone, Exercise, Bone Density, Densitometry, X-Ray, Double-Blind Method, Obesity, Body Composition, Blindness, Fats, Adipose Tissue, Placebos, Weight Loss, Body Weight, Diplopia, Lipids, HIV Infections, Humans, Female, Male, Adult, radiography

040711
MoOrB1059